7 集

Welcome to On the Frontlines of Multiple Sclerosis, a ReachMD series with the latest education and information on diagnostic and prognostic advancements and treatment options for patients with Multiple Sclerosis.

On the Frontlines of Multiple Sclerosis ReachMD

    • 科學

Welcome to On the Frontlines of Multiple Sclerosis, a ReachMD series with the latest education and information on diagnostic and prognostic advancements and treatment options for patients with Multiple Sclerosis.

    Is Primary Care Taking Full Advantage of Physical Therapy?

    Is Primary Care Taking Full Advantage of Physical Therapy?

    Host: Jennifer Caudle, DO

    Guest: Catherine Apicella, MPT, PYT-C, PRPC


    With less and less primary care physicians partnering with physical therapists, it’s time we ask: are we doing ourselves—and our patients—a disservice by not taking advantage of this option? To find out, Dr. Jennifer Caudle sits down with physical therapist Catherine Apicella to discuss the often-overlooked benefits of physical therapy and how primary care physicians and physical therapists can work together to benefit their patients.

    Detangling Difficult Conversations About Multiple Sclerosis: Clinical Exchanges

    Detangling Difficult Conversations About Multiple Sclerosis: Clinical Exchanges

    Host: Patricia K. Coyle, MD

    Guest: Clyde E. Markowitz, MD


    Multiple sclerosis (MS) is one of the leading causes of disability worldwide. As the treatment armamentarium continues to grow, patient involvement in the development of an effective treatment strategy is becoming increasingly important. In this Clinical ExchangesSM activity, leading MS specialists discuss issues of diagnosing MS, initiating treatment, and switching therapies, all in the context of practical shared decision-making techniques demonstrated by their own patients.

    Clinical Perspectives on Pregnancy & MS Patients

    Clinical Perspectives on Pregnancy & MS Patients

    Host: Shiv Saidha, MBBCh, MD, MRCPI

    Guest: Jiwon Oh, MD

    Guest: Kerstin Hellwig, MD


    Pregnancy is a major point of discussion for all women of child-bearing age, and when you factor in diseases like multiple sclerosis, it only further complicates matters. Hear from experts Dr. Kerstin Hellwig, Dr. Jiwon Oh, and Dr. Shiv Saidha about their approach to managing MS patients before, during, and after pregnancy.

    Reconsidering the Concept of First-Line, High-Efficacy Treatment

    Reconsidering the Concept of First-Line, High-Efficacy Treatment

    Host: Prof. Hans Peter Hartung



    In the management of multiple sclerosis there are essentially two therapeutic approaches. The first is a high-efficacy treatment typically reserved for patients with severe disease and a high number of relapses; the second is a slowly intensifying approach known as escalation in which less efficacious treatments are assessed before escalating to a second or third drug. High efficacy treatment comes with a higher risk/reward ratio than does escalation; but escalation can allow disease processes to continue beyond the window of opportunity for highest therapeutic benefit. How can clinicians make the correct choice for their patients?

    From Neuropathology to New Pathophysiological Concepts & Clinical Perspectives

    From Neuropathology to New Pathophysiological Concepts & Clinical Perspectives

    Host: Prof. Dr. Hans Lassmann


    The basic pathologic hallmark of multiple sclerosis is inflammation, but the causal factors involved in the formation of confluent plaques of demyelination and neurodegeneration in the brain, as well as loss of brain volume, have been difficult to elucidate. Efforts to identify downstream sequences leading to demyelination have resulted in the development of newer pharmacologic agents, but the larger questions are if, in the clinic, these agents are 1) really effective; and 2) focusing on the right targets?

    Burning Debate: B cells vs. T cells

    Burning Debate: B cells vs. T cells

    Host: Prof. David Wraith


    B cells have generally been considered to be only peripherally involved in the pathogenesis of multiple sclerosis. More recently, however, drug agents that deplete B cells have been shown to profoundly impact multiple sclerosis, greatly improving outcomes for patients affected by this autoimmune disease. Nonetheless, B-cell involvement in multiple sclerosis, for some, remains controversial.

關於科學的熱門 Podcast

聽眾還訂閱了